In the present systematic review and meta-analysis, we aimed to assess and highlight the most important polymorphic pharmacogenetic markers of the CYP3A4 gene associated with prostatic neoplasia, particularly with prostate cancer risk in European Caucasians. This evidence concerns the gene CYP3A4 and prostate cancer.